RIT with y 90 -ibritumomab tiuxetan in follicular non-hodgkin lymphoma: Evaluation of recent outcomes in a single institution

Abstract

Background. Based on historical data we reviewed our hospital clinical database to analyse our updated information and therapy outcomes of follicular non-Hodgkin lymphoma (F-NHL) patients treated with 90Y-Ibritumomab tiuxetan. Patients and Methods. Between 2005 and 2011, 56 F-NHL patients were included in a clinical protocol conducted by a multidisciplinary team and treated in the same centre. All patients received 0.3 or 0.4 mCi/kg IV (88) of 90Y-IT; response evaluation was performed 12 weeks after. Results. M/F 44.6/55.4, mean age 61.45 years (3085); ECOG 0-1 96.9. According to FLIPI score, distribution were good: 58.5, intermediate: 29.2, and poor: 12.3. Previous therapies: >2: 40 (26). ORR was 94.6 (53/56). CR: 85.7; CR according to previous disease: relapsed disease: 90 (27/30), refractory disease: 42.85 (3/7), consolidation with CR: 92.85 (13/14), and consolidation with PR: 100 (5/5). Global PR and NR were 8.9 (5) and 5.3 (3), respectively. Mean OS 63.86 months with a mean follow-up time of 57 months (273). Mean TTP: 52.65 months (95 CI: 43.8361.48). Median OS and TTP were not achieved. No hospital submissions or deaths were registered. Conclusions. This study confirms the safety and high efficacy of 90Y-IT in F-NHL patients, RIT in early stage of disease could improve outcomes. © 2012 Marcio Miguel Andrade Campos et al.